Siebert, N.; Leopold, J.; Zumpe, M.; Troschke-Meurer, S.; Biskupski, S.; Zikoridse, A.; Lode, H.N.
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers 2022, 14, 4842.
https://doi.org/10.3390/cancers14194842
AMA Style
Siebert N, Leopold J, Zumpe M, Troschke-Meurer S, Biskupski S, Zikoridse A, Lode HN.
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers. 2022; 14(19):4842.
https://doi.org/10.3390/cancers14194842
Chicago/Turabian Style
Siebert, Nikolai, Justus Leopold, Maxi Zumpe, Sascha Troschke-Meurer, Simon Biskupski, Alexander Zikoridse, and Holger N. Lode.
2022. "The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta" Cancers 14, no. 19: 4842.
https://doi.org/10.3390/cancers14194842
APA Style
Siebert, N., Leopold, J., Zumpe, M., Troschke-Meurer, S., Biskupski, S., Zikoridse, A., & Lode, H. N.
(2022). The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta. Cancers, 14(19), 4842.
https://doi.org/10.3390/cancers14194842